Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide-Reference-Cited by-同舟云学术

Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide

Published:2020-12 Issue:6 Volume:72 Page:
ISSN:0393-2249
Container-title:Minerva Urologica e Nefrologica
language:
Short-container-title:Minerva Urol Nefrol

Author:

Buttigliero Consuelo,Tucci Marcello,Sonetto Cristina,Vignani Francesca,Di Stefano Rosario F.,Pisano Chiara,Turco Fabio,Lacidogna Gaetano,Guglielmini Pamela,Numico Gianmauro,Scagliotti Giorgio V.,Di Maio Massimo

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2020N06A0737

Reference43 articles.

1. Cancer statistics, 2019

2. Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

3. Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study

4. Hormonal treatment and quality of life of prostate cancer patients: new evidence

5. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer;Reports of Practical Oncology and Radiotherapy;2024-01-23

2. Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel;Journal of Urologic Oncology;2023-11-30

3. Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study;Minerva Urology and Nephrology;2023-01

4. Comment on: "Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis";Minerva Urology and Nephrology;2022-05

5. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide;Minerva Urology and Nephrology;2022-02